ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Nevertheless, a phase II study that combined decitabine with Imatinib on a 28-patient CML cohort, showed an improvement in the survival for non-responder patients in advanced phase CML without BCR-ABL kinase mutation [116].